1187465-74-2

Upstream product

• 207981-46-2 2-fluoro-5-(trifluoromethyl)benzoyl chloride 
• 39222-73-6 2-Amino-5-t-butyl-1,3,4-thiadiazole 

Downstream Products

• 1217422-73-5 N-[(2Z)-5-tert-butyl-3-(tetrahydro-2H-pyran-2-ylmethyl)-1,3,4-thiadiazol-2(3H)-ylidene]-2-fluoro-5-(trifluoromethyl)benzamide 
• 1217422-76-8 (Z)-N-(5-tert-butyl-3-(3-cyanopropyl)-1,3,4-thiadiazol-2(3H)-ylidene)-2-fluoro-5-(trifluoromethyl)benzamide 
• 1217403-45-6 N-[(2Z)-5-tert-butyl-3-(3-cyanopropyl)-1,3,4-thiadiazol-2(3H)-ylidene]-2-(3-cyanopropoxy)-5-(trifluoromethyl)benzamide 
• 1217413-94-9 N-[(2Z)-3-butyl-5-tert-butyl-1,3,4-thiadiazol-2(3H)-ylidene]-2-fluoro-5-(trifluoromethyl)benzamide 
• 1187465-75-3 (S,Z)-N-(5-tert-butyl-3-((5-oxopyrrolidin-2-yl)methyl)-1,3,4-thiadiazol-2(3H)-ylidene)-2-fluoro-5-(trifluoromethyl)benzamide 

Relevant academic research and scientific papers

NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS

Disclosed herein are cannabinoid receptor ligands of formula (I) wherein A1, A5, Rx, X4, and z are as defined in the specification. Compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Compounds As Cannabinoid Receptor Ligands

Cannabinoid receptor ligands of formula (I) wherein Ring A and R1 are as defined in the specification. Compositions including such compounds, and methods of treating conditions and disorders using such compounds and compositions are also descri

NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS

Disclosed herein are compounds of formula (I) wherein R1, R2, R3, R25a, R26a, X, and n are as defined in the specification. Pharmaceutical compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and pharmaceutical compositions are also described